Are Peptides FDA Approved? The 2026 Status by Peptide

Of the peptides commonly prescribed through telehealth in 2026, semaglutide, tirzepatide, tesamorelin, bremelanotide (PT-141), and oxytocin have FDA approval histories for specific indications. Sermorelin once held an approval (since withdrawn for commercial reasons). BPC-157, CJC-1295, MOTS-c, and most performance or recovery peptides have never been submitted to the FDA for approval at all. The answer is more complicated than a simple yes or no, and understanding the distinction matters before you order anything.

1. Why this question is more complicated than it looks

"Are peptides FDA approved?" sounds like a yes/no question. It isn't. There are at least four meaningfully different situations a peptide can be in:

1. Currently FDA approved: the FDA has reviewed clinical trial data and authorized a specific manufacturer's product for a specific indication (e.g., semaglutide as Wegovy for obesity).
2. Previously approved, approval withdrawn: the brand was discontinued for non-safety commercial reasons after approval; the API may still be legally compoundable (e.g., sermorelin as Geref).
3. Never submitted: the peptide has human research behind it but no company has completed the NDA/BLA process (e.g., BPC-157, CJC-1295, TB-500).
4. Active IND, pre-approval: clinical trials are underway but approval has not been granted (e.g., elamipretide/SS-31 for Barth syndrome).

"FDA approved" and "legal" are also not the same thing. A compound can be legal to prescribe and dispense through a 503A pharmacy without having received FDA drug approval. We address that distinction in Are peptides legal in the United States?

2. The three FDA categories for peptides (approved, withdrawn, never submitted)

Category A: Currently FDA-approved peptides

These peptides have completed the FDA's drug approval process and are available as commercially manufactured branded products. Compounded versions may also exist legally under 503A, but only under specific circumstances (shortage status, patient-specific needs, etc.).

• Semaglutide: GLP-1 receptor agonist; approved as Ozempic (2017, T2DM) and Wegovy (2021, obesity)
• Tirzepatide: dual GIP/GLP-1 agonist; approved as Mounjaro (2022, T2DM) and Zepbound (2023, obesity)
• Tesamorelin: GHRH analog; approved as Egrifta (2010, HIV-associated lipodystrophy)
• Bremelanotide (PT-141): MC4R agonist; approved as Vyleesi (2019, HSDD in premenopausal women)
• Oxytocin: nonapeptide hormone; approved as Pitocin (1953, labor induction/postpartum hemorrhage)

Category B: Withdrawn approvals

These peptides had FDA approval but the brand was discontinued, typically for commercial, not safety, reasons. The API often remains on the compoundable drug list.

• Sermorelin (Geref): GHRH analog; FDA approved in 1997 for GH deficiency in children; manufacturer voluntarily withdrew the product ~2008; the API remains Category 1 compoundable

Category C: Never submitted to the FDA

These peptides have research literature, often substantial animal data, sometimes human case series, but have never completed (or in most cases even started) the formal NDA/BLA process with the FDA.

• BPC-157 (Body Protection Compound-157)
• CJC-1295 (modified GHRH analog)
• Ipamorelin (ghrelin mimetic)
• MOTS-c (mitochondrial-derived peptide)
• Epithalon (Epitalon)
• GHK-Cu (copper tripeptide)
• TB-500 / Thymosin Beta-4
• Kisspeptin
• Dihexa
• AOD-9604

3. FDA-approved peptides table

The table below covers every peptide commonly prescribed through US peptide telehealth services in 2026. Columns: FDA status, original approval year (if any), current branded products, and compounding availability under 503A.

4. Withdrawn approvals: Sermorelin Geref and the compounding pathway that followed

Sermorelin (GRF 1-29) was approved by the FDA in 1997 under the brand name Geref for the treatment of idiopathic growth hormone deficiency in children. The manufacturer voluntarily withdrew the product from the US market around 2008, not because of safety concerns, but because the GH deficiency market shifted toward recombinant human growth hormone (rhGH) products. Geref became commercially unviable.

When a previously approved drug is discontinued, its active pharmaceutical ingredient (API) can typically be added to or retained on the compoundable drug list maintained by the FDA and used by compounding accreditation bodies. Sermorelin's API remains on Category 1 of that list, which means accredited 503A compounding pharmacies can legally compound it for patient-specific prescriptions.

The practical result: sermorelin has more clinical history and regulatory scrutiny behind it than most peptides, making it one of the more defensible growth hormone peptides to prescribe and compound. It also means there is no branded product to reference for dosing guidance, providers rely on the primary literature and the GHRH mechanism.

5. Peptides compounded under 503A pharmacy law

Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) creates a patient-specific compounding exemption. Under this exemption, a licensed pharmacist may compound a drug product, including peptides that have not received FDA approval, when:

1. A licensed practitioner writes a valid patient-specific prescription
2. The pharmacy is state-licensed and operating under USP <797> sterile compounding standards
3. The active ingredient is not on the FDA's Category 2 (prohibited) list
4. The drug is not essentially a copy of a commercially available product that the patient could reasonably use

For most of the peptides in the table above, BPC-157, CJC-1295, MOTS-c, ipamorelin, GHK-Cu, etc., conditions 1 through 3 are satisfied when a telehealth provider writes the prescription and a 503A pharmacy fills it. Condition 4 is satisfied because there is no commercially available branded equivalent.

RxPepsDirect prescriptions are filled by Optimal Balance Pharmacy, an accredited 503A facility. Every vial ships with a Certificate of Analysis documenting sterility, endotoxin levels, and potency for the specific lot.

6. What FDA approval means, and what it doesn't mean

FDA approval means the agency reviewed the manufacturer's clinical trial data and concluded that the drug is safe and effective for a specific indication, at a specific dose, manufactured by a specific facility. It does not mean:

• The drug is the only safe option for a condition
• Unapproved alternatives are necessarily unsafe or ineffective
• The drug cannot be used off-label for other indications
• Compounded versions are substandard (compounding is regulated separately under USP <797> and state board oversight)

The FDA drug approval process is designed around commercially manufactured products sold at scale. The 503A framework exists precisely because that process is not appropriate for patient-specific compounds, it would be like requiring individual bakeries to go through commercial food manufacturing certification for a custom wedding cake.

7. The compounded version question: is the compounded peptide FDA approved?

No compounded drug product is ever "FDA approved." This is true even when the active ingredient has full FDA approval. Compounded tirzepatide is not FDA approved. Compounded oxytocin is not FDA approved. Compounded semaglutide is not FDA approved. What is FDA approved is the active ingredient's safety and efficacy data (as reviewed in the NDA or BLA), not any particular compounded formulation.

The compounded product is legal because it operates under the Section 503A exemption, not because it has been through the NDA process. This distinction matters:

• The compound has not undergone the FDA's pre-market review of its specific formulation
• Quality assurance comes from USP <797> compounding standards, state board oversight, and per-lot lab testing, not from the FDA's manufacturing inspection process
• Patients should ask their pharmacy for a Certificate of Analysis (COA) documenting sterility, endotoxin, and potency for every lot they receive

For more on the difference between compounded and research-grade peptides, see our guide: Compounded peptides vs research peptides: a 2026 buyer's guide.

8. How to verify FDA approval status yourself

You don't have to take anyone's word for a peptide's FDA approval status. The FDA makes its approved drug database publicly searchable:

1. Drugs@FDA (accessdata.fda.gov/scripts/cder/daf), search by drug name, active ingredient, or NDA/BLA number. If a peptide has current FDA approval, it will appear here with approval date, indication, and the full label.
2. DailyMed (dailymed.nlm.nih.gov), maintained by the NIH, this database includes the full package insert for every FDA-approved drug and many compounded preparations.
3. FDA's Orange Book: lists approved drug products with therapeutic equivalence evaluations. Useful for checking patent status and generic availability.

If you search Drugs@FDA for "BPC-157," "CJC-1295," or "MOTS-c" and find no results, that confirms those peptides have no FDA-approved drug product. If you search for "semaglutide," you will find the Ozempic, Wegovy, and Rybelsus NDA entries with full labeling.

9. The legality vs FDA approval distinction

The most important practical distinction for a peptide patient is not "is this FDA approved?" but rather "is this legal to obtain with a prescription, and is the source legitimate?"

Under US law, a peptide can be:

• FDA approved + legally obtainable: semaglutide, tirzepatide, tesamorelin, bremelanotide, oxytocin, all available through standard pharmacy channels with a prescription
• Not FDA approved + legally obtainable through 503A: BPC-157, CJC-1295, sermorelin, ipamorelin, MOTS-c, GHK-Cu, and most therapeutic peptides, available through licensed telehealth + 503A pharmacy with a prescription
• Not FDA approved + legal gray area: peptides sold as "research chemicals" or "not for human use" without a prescription, technically legal as long as not sold for human use, but this is a legal fiction most vendors and buyers acknowledge is thin
• Controlled substances: some compounds (not peptides, but often conflated) are Schedule I or II, making them illegal regardless of prescription status

For the full legal analysis, including state-by-state variation and WADA implications, see our guide: Are peptides legal in the United States in 2026?

The short version: getting a prescription from a licensed provider and filling it at an accredited 503A pharmacy is the legitimate pathway for any therapeutic peptide, approved or not. It is how RxPepsDirect operates. Learn more about the compounded tirzepatide legal question specifically.